T his 4-year-old boy was seen by his pediatrician for a yellow bump on his knee and he ended up receiving a liver transplant.
Robert Listernick, MD, moderator: I thought I would try being succinct for a change. Yellow bumps?
Anthony J. Mancini, MD, pediatric dermatologist: There are basically two types of yellow bumps in pediatrics outside of the neonatal period that are both xanthomatous lesions -juvenile xanthogranulomas (JXG) and xanthomas. Xanthomas are groups of lipidladen macrophages that can present with various morphologies, including macules, papules, plaques, and nodules. Xanthomas are rare in childhood but, when present, are highly suggestive of a disorder of lipid metabolism. Eruptive xanthomas are small, red-yellow papules that are predominantly found on extensor surfaces. They are most often associated with disorders of primary or secondary triglyceridemia. This is the one group of xanthomas that rapidly disappear if elevated triglyceride levels are normalized. Tuberous xanthomas, which range from pink-yellowish small papules to large plaques, are generally on extensor surfaces and associated with hypercholesterolemic disorders.
Dr. Listernick: And JXGs? Dr. Mancini: JXGs are a fairly common form of non-Langerhans cell histiocytosis. They may be micronodular or macronodular. JXGs are easily distinguished from xanthomas, as the former are comprised of foamy cells and scattered histiocytes. Although yellowishorange, JXGs have nothing to do with disordered lipid metabolism.
Dr. Listernick: I'll just chime in that there's a rare association in children who have neurofibromatosis type 1 (NF1) between the presence of JXGs and the development of juvenile myelomonocytic leukemia (JMML). I stress that it's a rare association, as in our clinic of 60 to 70 children with JXGs, none has developed JMML. We don't perform "screening" blood counts on these children nor do we even discuss this rare association with the families, as it simply causes needless anxiety.
Dr. Mancini: There are many more types of xanthomatous lesions but that discussion is well beyond the scope of this conference.
Dr. Listernick: Moving forward, the family history is remarkable in that both parents are of Mexican descent and they are first cousins. They reportedly have no other health problems. The mother is overweight but the father is of normal weight. They do not have elevated blood pressure or suffer from type 2 diabetes.
The maternal grandmother is overweight but has no health issues. The maternal grandfather died at age 45 years of myocardial infarction and had type 2 diabetes. There's one maternal aunt with hyperlipidemia, but no further history is available. The patient's medical history is remarkable only for iron-deficiency anemia. His birth history and development were normal.
On physical exam, he was healthy appearing. Weight and height were in the 25th percentiles. Body mass index was 15. Blood pressure was normal, and his exam was unremarkable save for multiple biopsy-confirmed xanthomas.
Laboratory evaluation was as follows: total cholesterol of 1,125 mg/dL, triglycerides of 171 mg/dL, high-density lipoprotein (HDL) cholesterol of 38 mg/ dL, and low-density lipoprotein (LDL) cholesterol of 946 mg/dL. Complete blood count, liver function tests, and thyroid functions were all normal. I'm going to stop there for a second. Both parents' total cholesterol values were over 300 mg/dL, but I don't have their complete lipid profiles.
Let's back up a bit. What is the pediatrician's role in lipid screening?
Irwin Benuck, MD, PhD, pediatrician: According to the latest set of recommendations from the Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, the guidelines can be summarized by age. Between ages 1 Firm Rounds year and 9 years, the panel recommended fasting lipid profile only if the family history is positive for cardiovascular disease, if a parent has dyslipidemia, or if the child has any other risk factors for early-onset coronary artery disease, such as chronic renal failure or history of Kawasaki disease. Universal lipid screening is recommended for children between ages 9 years and 11 years, by either nonfasting, non-HDL or fasting lipid profile. Levels of non-HDL cholesterol (total cholesterol minus HDL) appear to be most predictive of future atherosclerosis. This is quite convenient, because non-HDL cholesterol can be measured accurately in the nonfasting state.
Dr. Listernick: Are these guidelines evidence-based? Dr. Benuck: They are a combination of both evidence-based recommendations as well as expert consensus based on extant information.
Dr. Listernick: What types of lipid profiles are generally seen?
Dr. Benuck: Since obesity has become so prevalent in the United States, the most common dyslipidemia seen is a combined pattern with mild elevation of total cholesterol and LDL cholesterol, moderate to severe elevation of serum triglycerides, and low levels of HDL.
Dr. Listernick: For this more common dyslipidemia associated with obesity, what treatment recommendations were made? Dr. Benuck: First and foremost is lifestyle modification -increasing physical activity, losing weight, and a sensible diet limiting cholesterol and saturated and trans fats. Pharmacologic treatment with a statin is generally recommended when the LDL cholesterol is higher than 190 mg/dL despite 6 months of lifestyle changes in children older than age 10 years. If there is a strong family history, treatment might be started at lower levels of LDL cholesterol. Dr. Benuck: Statins don't work in these patients. His LDL cholesterol was lowered by 100 mg/dL, which is just "a drop in the bucket." The other two therapies considered were LDL apheresis and liver transplantation.
Gal Finer, MD, pediatric kidney diseases physician: In essence, blood is drawn from the patient through a venous access and pumped into a plasma separator into one of two columns that provide LDL absorption. These columns actually work in tandem to maximize the efficiency. The LDL is eluted and discarded through the waste line and LDL-free plasma is returned to the patient after it recombines with the patient's cells. The procedure typically takes about 2 to 3 hours. This treatment doesn't remove albumin, immunoglobulin, or HDL, and it is typically provided every 2 to 3 weeks.
Dr. Listernick: In general, what are the indications for LDL apheresis?
Dr. Finer: Basically, all patients with homozygous familial hypercholesterolemia and some heterozygotes who are refractory to treatment with medications. It has been shown to improve coronary artery disease outcomes, slow progression of atherosclerosis, and improve endothelial function. However, it is extremely difficult to achieve normal cholesterol levels in homozygous patients. The typical patient usually starts with plasma LDL cholesterol levels between 500 mg/dL and 1,000 mg/dL, which is lowered to 100 mg/dL to 200 mg/dL, and then rebounds before the next cycle. Still, about 20% of the patients receiving apheresis have progressive cardiovascular disease. Lipid apheresis is considered safe and has low rate of adverse events. Unless liver transplantation is performed, this treatment needs to be provided for life.
Dr. Listernick: Computed tomography angiography (CTA) of his coronary arteries 1 year ago was normal. However, recent coronary angiography in preparation for liver transplantation revealed discrete 60% narrowings of both the left main and left anterior descending coronary arteries, as well as severe stenosis of the proximal portion of the first large marginal branch. Did his coronary artery disease progress rapidly over 1 year or is CTA not sensitive in children?
Steven Kindel, MD, pediatric cardiologist: CTA is good for detecting calcium deposits in the walls of the arteries. This child probably has cholesterol plaques that haven't yet calcified. In addition, heart rate affects our ability to visualize small arteries. Young children have much higher heart rates than adults, which is probably a factor in our inability to visualize his lesions with CTA. He also probably developed progressive disease over the year.
Dr. Listernick: Is he likely to develop angina from this degree of coronary disease?
Dr. Kindel: It's difficult to say. He may have developed extensive collateralization of vessels, limiting symptoms. Angina in this age group is rare even with significant coronary disease.
Dr. Listernick: So what do we do with these results? Dr. Kindel: There was a lot of discussion and debate. Once the decision was made to offer liver transplantation to the child, there was concern about the risk of cardiac decompensation during and after transplantation. In addition, there was concern that a myocardial infarction prior to transplantation would put him at greater risk during the surgery. Finally, the decision was made to perform coronary revascularization prior to liver transplantation.
Peter Whitington, MD, pediatric hepatologist: This is clearly a difficult decision but, for what it's worth, if an adult were in a similar situation, coronary revascularization almost certainly would not be performed.
Dr. Listernick: Why does liver transplantation work?
Dr. Whitington: The healthy liver has a full complement of LDL receptors that scavenge the LDL. The disease is totally corrected. In addition, much of the coronary artery disease may disappear post-transplant.
Dr. Listernick: Let's say the parents produce another affected child. How would you approach his treatment? Dr. Whitington: That's an ongoing debate. Early liver transplantation is not an easy therapy, but it might be easier than life-long LDL apheresis. My personal opinion is that I would offer a child who has homozygous hypercholesterolemia liver transplantation at 1 year of age.
Dr. Listernick: Could one of the parents be a donor? Dr. Whitington: No. They are heterozygotes for familial hypercholesterolemia and we would be committing this child to life-long serum cholesterol levels in the range of 300 mg/dL, which is not a particularly healthy situation.
Dr. Listernick: Could you use part of the liver of the healthy 8-year-old brother who has normal cholesterol?
Dr. Whitington: The youngest living related donor we have used was 18 years of age.
Dr. Listernick: Thank you, everybody.
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